Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2019 08:20 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of...
October 15, 2019 23:17 ET | Source: ProQR Therapeutics N.V.

ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the...
October 15, 2019 16:13 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of...
October 15, 2019 16:08 ET | Source: ProQR Therapeutics N.V.

ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
October 11, 2019 06:02 ET | Source: ProQR Therapeutics N.V.

ProQR gibt positive Top-Line-Ergebnisse aus der Phase-1/2-Studie mit Sepofarsen bei LCA10-Patienten bekannt

Bericht spricht von schnellen, signifikanten und dauerhaften Verbesserungen der Sehkraft nach zwölf MonatenKonkordante Verbesserung bei den Messungen der wichtigsten sekundären ErgebnisseFür die...
October 11, 2019 06:02 ET | Source: ProQR Therapeutics N.V.

ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10

Des améliorations rapides, significatives et durables de la vision à douze mois ont été rapportéesAmélioration concordante des mesures des résultats secondaires clésLa dose d'enregistrement cible du...
October 10, 2019 06:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...
October 07, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
September 30, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at Two Investor Conferences in October

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
September 09, 2019 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...